Arcutis Biotherapeutics' Zoryve drives revenue growth and nears cash flow positivity, yet high valuation warrants a Hold ...
A new cohort study published in Journal of American Medical Association suggests that biologics targeting IL-12, IL-23, and ...
A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback